Literature DB >> 16712796

A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy.

Vlad C Vasile1, Steve R Ommen, William D Edwards, Michael J Ackerman.   

Abstract

The R975W mutation, in the alternatively spliced exon 19 of vinculin (VCL) which yields the isoform metavinculin, was associated previously with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), and shown to alter in vivo organization of intercalated discs. We tested the hypothesis that alterations in the ubiquitously expressed, VCL-encoded protein, vinculin, may provide a pathogenic substrate for HCM. Comprehensive mutational analysis of VCL's 22 translated exons was performed in a cohort of 228 unrelated patients with genotype negative HCM, having no identifiable mutations in 12 HCM-associated myofilament/Z-disc-encoding genes. A novel missense mutation, L277M-VCL, involving a conserved residue was identified in a patient with severely obstructive, mid-ventricular hypertrophy. This mutation was not detected in 400 reference alleles. Immunohistochemical analysis of the proband's myectomy specimen demonstrated markedly reduced vinculin levels in the intercalated discs. We provide the first report of a cardiomyopathy associated mutation in vinculin. Despite its ubiquitous expression, the HCM-associated VCL mutation clinically yielded a cardiac-specific phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16712796     DOI: 10.1016/j.bbrc.2006.04.151

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  38 in total

Review 1.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

Review 2.  Molecular genetics and pathogenesis of cardiomyopathy.

Authors:  Akinori Kimura
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

Review 3.  The integrin adhesome: from genes and proteins to human disease.

Authors:  Sabina E Winograd-Katz; Reinhard Fässler; Benjamin Geiger; Kyle R Legate
Journal:  Nat Rev Mol Cell Biol       Date:  2014-04       Impact factor: 94.444

4.  Vinculin directly binds zonula occludens-1 and is essential for stabilizing connexin-43-containing gap junctions in cardiac myocytes.

Authors:  Alice E Zemljic-Harpf; Joseph C Godoy; Oleksandr Platoshyn; Elizabeth K Asfaw; Anna R Busija; Andrea A Domenighetti; Robert S Ross
Journal:  J Cell Sci       Date:  2014-01-10       Impact factor: 5.285

Review 5.  Cell-cell connection to cardiac disease.

Authors:  Farah Sheikh; Robert S Ross; Ju Chen
Journal:  Trends Cardiovasc Med       Date:  2009-08       Impact factor: 6.677

Review 6.  New insights into vinculin function and regulation.

Authors:  Xiao Peng; Elke S Nelson; Jessica L Maiers; Kris A DeMali
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

Review 7.  Integrins and integrin-associated proteins in the cardiac myocyte.

Authors:  Sharon Israeli-Rosenberg; Ana Maria Manso; Hideshi Okada; Robert S Ross
Journal:  Circ Res       Date:  2014-01-31       Impact factor: 17.367

Review 8.  Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy.

Authors:  Andrew P Landstrom; Michael J Ackerman
Journal:  Circulation       Date:  2010-12-07       Impact factor: 29.690

Review 9.  Vinculin and talin: focus on the myocardium.

Authors:  Alice Zemljic-Harpf; Ana Maria Manso; Robert S Ross
Journal:  J Investig Med       Date:  2009-12       Impact factor: 2.895

10.  The vinculin-DeltaIn20/21 mouse: characteristics of a constitutive, actin-binding deficient splice variant of vinculin.

Authors:  Susanna Marg; Ulrike Winkler; Marcello Sestu; Mirko Himmel; Madeleine Schönherr; Janina Bär; Amrit Mann; Markus Moser; Claudia T Mierke; Klemens Rottner; Manfred Blessing; Johannes Hirrlinger; Wolfgang H Ziegler
Journal:  PLoS One       Date:  2010-07-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.